Wuxi Pharmatech (Cayman) Inc raises FY 2014 outlook; gives Q3 2014 outlook in line with analysts' estimates


Wednesday, 13 Aug 2014 04:30pm EDT 

Wuxi Pharmatech (Cayman) Inc:Raised FY 2014 revenue guidance range from the previous $660-$670 mln to $665-$670 million.Increased FY 2014 GAAP diluted earnings per ADS of $1.55-$1.59, compared to previous guidance of $1.53-$1.58.Increased FY 2014 Non-GAAP diluted earnings per ADS of $1.82-$1.86, compared to previous guidance of $1.80-$1.85.Expects Q3 2014 total net revenues of $171-$173 mln.Expects Q3 2014 GAAP diluted earnings per ADS of $0.40-$0.42.Expects Q3 2014 non-GAAP diluted earnings per ADS of $0.48-$0.50.FY 2014 revenue of $669 mln, EPS of $1.84 - Thomson Reuters I/B/E/S.Q3 2014 revenue of $173 mln, EPS of $0.49 - Thomson Reuters I/B/E/S. 

Company Quote

39.95
-0.59 -1.46%
27 Feb 2015